Novartis India Limited

July 29, 2026

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500 672

Subject: Disclosure in terms of Regulation 29 (2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) ("SAST") Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and as amended from time to time, please find enclosed herewith the disclosure regarding the **sale** of equity shares of **Novartis India Limited** ("the Company").

This disclosure is filed in connection with the sale of 1,74,50,680 (One Crore Seventy-Four Lakhs Fifty Thousand Six Hundred and Eighty Only) equity shares (representing 70.68% (Seventy point Sixty-Eight) of the total share capital) by Novartis AG on Wednesday, July 29, 2026.

Kindly take the above information on record and acknowledge receipt.

The disclosure will also be made available on the Company's website at www.nilpharma.co.in.

Yours sincerely,
For Novartis India Limited

CHANDNI BHUPENDRA MARU
Digitally signed by CHANDNI BHUPENDRA MARU
Date: 2026.07.29 19:10:13 +05'30'

Chandni Maru
Company Secretary and Compliance Officer
A60291

Encl as above:

Novartis AG
CH-4002 Basel
Switzerland

https://www.novartis.com
https://x.com/novartisnews

July 29, 2026

To,

1. **The Secretary,**
   BSE Limited
   Phiroze Jeejeebhoy Towers
   Dalal Street,
   Mumbai - 400 001
   Maharashtra, India

2. **The Board of Directors,**
   Novartis India Limited
   Inspire BKC, 7th Floor,
   Bandra Kurla Complex,
   Bandra East, Mumbai 400 051,
   Maharashtra, India.

   Scrip Code: 500672

Sub : Disclosure under Regulation 29 (2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dear Sir / Ma'am:

We, Novartis AG, hereby make this disclosure pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

We request you to kindly take the above on record and acknowledge receipt.

[*Signature pages follow*]

Yours faithfully,

For and on behalf of **NOVARTIS AG**

Name: Eric Careau
Designation: Attorney

[*Signature Page – Disclosure by Novartis AG under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011*]

Yours faithfully,

For and on behalf of **NOVARTIS AG**

Name: OLIVER WATSON
Designation: AUTHORISED SIGNATORY

[*Signature Page – Disclosure by Novartis AG under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011*]

Novartis AG
CH-4002 Basel
Switzerland

https://www.novartis.com
https://x.com/novartisnews

Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 read with SEBI Master circular SEBI/HO/CFD/PoD-1/P/CIR/2023/31 dated February 16, 2023

Name of the Target Company (TC)	Novartis India Limited ("**Target Company**")		
Name(s) of the Seller	Novartis AG ("**Seller**")		
Whether the Seller belongs to Promoter/Promoter group	Yes, the Seller was the promoter of the Target Company. However, pursuant to the completion of the present sale of the equity shares of the Target Company, the Seller has ceased to hold any equity shares of the Target Company and stands reclassified from 'promoter' to 'public' category shareholder of the Target Company in accordance with Regulation 31A(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited		
Details of the ~~acquisition~~ ~~/~~disposal as follows	Number	% w.r.t.total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the sale under consideration, holding of :			
a) Shares carrying voting rights	1,74,50,680	70.68%	70.68%
~~b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)~~			
~~c) Voting rights (VR) otherwise than by shares~~			
~~d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)~~			
e) Total (a+b+c+d)	1,74,50,680	70.68%	70.68%
Details of ~~acquisition~~/sale			
a) Shares carrying voting rights ~~acquired~~/sold	1,74,50,680	70.68%	70.68%
b) ~~VRs acquired /sold otherwise than by shares~~			
c) ~~Warrants/convertible securities/any other instrument that entitles the~~			

Novartis AG
CH-4002 Basel
Switzerland

https://www.novartis.com
https://x.com/novartisnews

~~acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold~~ d) ~~Shares encumbered / invoked/released by the acquirer~~ e) Total (a+b+c+/-d)	1,74,50,680	70.68%	70.68%
After the ~~acquisition/~~sale, holding of: a) Shares carrying voting rights ~~b) Shares encumbered with the acquirer~~ ~~c) VRs otherwise than by shares~~ ~~d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition~~ e) Total (a+b+c+d)	NIL NIL	NIL NIL	NIL NIL
Mode of ~~acquisition /~~ sale ~~(e.g. open market /~~ off-market ~~/ public issue / rights issue / preferential allotment / inter-se transfer etc).~~	Off market sale pursuant to the Agreement for the sale and purchase of the Sale Shares in Novartis India Limited dated February 19, 2026.		
Date of ~~acquisition /~~ sale of shares ~~/ VR or date of receipt of intimation of allotment of shares, whichever is applicable~~	Wednesday, July 29, 2026		
Equity share capital / total voting capital of the TC before the said ~~acquisition~~ / sale	INR 12,34,53,985 comprising of 2,46,90,797 fully paid-up equity shares of face value of INR 5 each		
Equity share capital/ total voting capital of the TC after the said ~~acquisition~~ / sale	INR 12,34,53,985 comprising of 2,46,90,797 fully paid-up equity shares of face value of INR 5 each		
Total diluted share/voting capital of the TC after the said ~~acquisition~~ / sale	INR 12,34,53,985 comprising of 2,46,90,797 fully paid-up equity shares of face value of INR 5 each		

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the Target Company to the Stock Exchange under Clause 35 of the listing Agreement or Regulation 31 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

[*Signature pages follow*]

Yours faithfully,

For and on behalf of **NOVARTIS AG**

Name: Eric Careau
Designation: Attorney

[*Signature Page – Disclosure by Novartis AG under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011*]

Yours faithfully,

For and on behalf of **NOVARTIS AG**

Name: OLIVER WATSON
Designation: AUTHORISED SIGNATORY